Shareholders Will Probably Hold Off On Increasing Nightingale Health Oyj's (HEL:HEALTH) CEO Compensation For The Time Being

Key Insights

• Nightingale Health Oyj to hold its Annual General Meeting on 6th of November
• Total pay for CEO Teemu Suna includes €364.0k salary
• Total compensation is 224% above industry average
• Over the past three years, Nightingale Health Oyj's EPS fell by 0.9% and over the past three years, the total shareholder return was 84%

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

The share price of Nightingale Health Oyj (HEL:HEALTH) has increased significantly over the past few years. However, the earnings growth has not kept up with the share price momentum, suggesting that some other factors may be driving the price direction. The upcoming AGM on 6th of November may be an opportunity for shareholders to bring up any concerns they may have for the board’s attention. They will be able to influence managerial decisions through the exercise of their voting power on resolutions, such as CEO remuneration and other matters, which may influence future company prospects. In our analysis below, we show why shareholders may consider holding off a raise for the CEO's compensation until company performance improves.

View our latest analysis for Nightingale Health Oyj

How Does Total Compensation For Teemu Suna Compare With Other Companies In The Industry?

Our data indicates that Nightingale Health Oyj has a market capitalization of €131m, and total annual CEO compensation was reported as €1.1m for the year to June 2025. That's a notable decrease of 33% on last year. While this analysis focuses on total compensation, it's worth acknowledging that the salary portion is lower, valued at €364k.

In comparison with other companies in the Finland Healthcare industry with market capitalizations ranging from €86m to €346m, the reported median CEO total compensation was €350k. This suggests that Teemu Suna is paid more than the median for the industry. Moreover, Teemu Suna also holds €5.8m worth of Nightingale Health Oyj stock directly under their own name, which reveals to us that they have a significant personal stake in the company.

On an industry level, around 57% of total compensation represents salary and 43% is other remuneration. Nightingale Health Oyj pays a modest slice of remuneration through salary, as compared to the broader industry. It's important to note that a slant towards non-salary compensation suggests that total pay is tied to the company's performance.

Nightingale Health Oyj's Growth

Over the last three years, Nightingale Health Oyj has not seen its earnings per share change much, though they have deteriorated slightly. In the last year, its revenue is up 7.7%.

A lack of EPS improvement is not good to see. And the modest revenue growth over 12 months isn't much comfort against the reduced EPS. It's hard to argue the company is firing on all cylinders, so shareholders might be averse to high CEO remuneration. Historical performance can sometimes be a good indicator on what's coming up next but if you want to peer into the company's future you might be interested in this free visualization of analyst forecasts.

Has Nightingale Health Oyj Been A Good Investment?

Most shareholders would probably be pleased with Nightingale Health Oyj for providing a total return of 84% over three years. So they may not be at all concerned if the CEO were to be paid more than is normal for companies around the same size.

In Summary...

Despite the strong returns on shareholders' investments, the fact that earnings have failed to grow makes us skeptical about the stock keeping up its current momentum. In the upcoming AGM, shareholders will get the opportunity to discuss any concerns with the board, including those related to CEO remuneration and assess if the board's plan will likely improve performance in the future.

CEO compensation is an important area to keep your eyes on, but we've also need to pay attention to other attributes of the company. That's why we did our research, and identified 2 warning signs for Nightingale Health Oyj (of which 1 is a bit concerning!) that you should know about in order to have a holistic understanding of the stock.

Of course, you might find a fantastic investment by looking at a different set of stocks. So take a peek at this free list of interesting companies.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.